DigestAID

What DigestAID does

DigestAID (legal entity: DIGESTAID – Artificial Intelligence Development, Lda.) is a Porto, Portugal-based private medical-device company that develops AI-powered software for the detection and classification of lesions across the digestive and pancreatobiliary tracts. Founded in 2019, the company has built a portfolio of nine products organized into three clusters: capsule endoscopy (Deep Capsule, GI Spy, IBD Smart), AI live vision for cholangioscopy, endoscopic ultrasound, high-resolution anoscopy and device-assisted enteroscopy (Smart Cholangio, Smart Pancreas, Anoscopy Genius, Deep Bowel), and digestive motility analytics (Smart Mano, Smart Esophagus). All products are built on custom-designed Convolutional Neural Networks trained on a corpus of more than 2 million exams from world-renowned institutions, with reported diagnostic accuracy above 90% and over 100,000 exams processed in deployment.

The underlying platform processes video (up to 50,000 frames per capsule study), images, and structured manometry data through tailor-made CNNs that classify lesions and prioritize them by severity, with external cloud servers providing compute. DigestAID claims multi-brand device compatibility across the installed base of endoscopy equipment and holds eight patent applications, including a granted 20-year DeepCapsule patent, supported by 200+ peer-reviewed publications and multiple ACG Presidential Poster Awards. Clinical validation partnerships with the University of South Alabama, Hospital Universitario Puerta del Hierro, and the World Gastroenterology Organization anchor the evidence base, with the Medical R&D Chairman also serving as WGO President.

Commercially, DigestAID operates a B2B enterprise field-sales motion selling AI software subscriptions to gastroenterology practices, hospitals, GI endoscopy centers, and hepatopancreatobiliary specialists, with quote-based pricing, annual billing, and IFU-documented medical-device positioning. Pricing is not publicly disclosed, no funding rounds or revenue figures are reported, and the company appears to be in a clinical-validation and pre-commercial clearance phase while expanding its international footprint into Spain, Brazil, and the United States.

Name

DigestAID

Legal name

DIGESTAID – Artificial Intelligence Development, Lda.

Website

https://digestaid.health

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

DigestAID is a Porto-based AI medical-device company that builds deep learning software for lesion detection across the digestive and pancreatobiliary tracts, serving gastroenterology hospitals, endoscopy centers, and hepatopancreatobiliary specialists through enterprise sales.

Ownership category

akta.pro rank

Product category

Gastroenterology AI Diagnostic Software

NAICS

Computer Systems Design and Related Services (54151), Medical Laboratories (621511)

SIC

Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industries

Diagnostic & Triage Decision Support (HLACAGAA), Advanced Endoscopy (ERCP/EUS/Interventional) (HLAKAEAC), Inflammatory Bowel Disease (IBD) Care (HLAKAEAD)

Keywords

• AI endoscopy solutions
• Capsule endoscopy analysis
• Gastroenterology AI software
• Medical imaging AI
• Lesion detection software

Headquarters

HQ city

Porto

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. AI Software Licensing: The company appears to license its AI software technology to healthcare institutions. Products like Deep Capsule have Instructions for Use (IFU) documents, suggesting regulatory-approved medical device software sales.
2. Clinical Validation Services: Partnerships with healthcare institutions for technology validation and development, suggesting service-based revenue components.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

DigestAID develops AI-powered medical device software for digestive healthcare, applying custom-designed Convolutional Neural Networks to automatically detect and classify lesions during endoscopic procedures. Its portfolio spans capsule endoscopy, cholangioscopy, endoscopic ultrasound, high-resolution anoscopy, device-assisted enteroscopy, and anorectal/esophageal manometry. The products serve gastroenterologists and hospitals by prioritizing urgent findings, reducing manual review time, and improving diagnostic accuracy above 90%.

Product overview

DigestAID is a portfolio of AI-powered medical devices and software solutions for digestive healthcare, organized into three main technology clusters. The Capsule Endoscopy cluster includes Deep Capsule (small bowel), GI Spy (panendoscopic colon capsule), and IBD Smart (Crohn's disease detection). The AI Live Vision cluster covers cholangioscopy (Smart Cholangio), endoscopic ultrasound (Smart Pancreas), anoscopy (Anoscopy Genius), and device-assisted enteroscopy (Deep Bowel). The Digestive Motility cluster includes Smart Mano (anorectal manometry) and Smart Esophagus (esophageal manometry). All products utilize proprietary deep learning convolutional neural networks for automatic lesion detection and classification, with external cloud servers providing computing power.

Differentiator

Problem solved

Functional benefit

Products and services

• Deep Capsule

Quantifiable outcome

• Global diagnostic accuracy >90% across AI solutions
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core.

• University of South AlabamacoreStrategic or Co-development Partner · 13 December 2023Global collaboration with University of South Alabama and Dr. Jack Di Palma (Master and Past President of American College of Gastroenterology) to develop and validate capsule endoscopy technologies for transformative software development.
• Hospital Universitario Puerta del HierrocoreStrategic or Co-development Partner · 11 November 2023International collaboration for SmartCyst and SmartCholangio technologies. Dr. Belen Agudo Castillo and Dr. Mariano González-Haba Ruiz presented studies on pancreatic cystic lesions and biliary strictures using DigestAID technology.
• World Gastroenterology Organization (WGO)coreStrategic or Co-development PartnerPartnership with WGO, whose President Guilherme Macedo serves as DigestAID's Medical R&D Chairman. Strategic alignment for advancing digestive healthcare globally.
• iCARE Group (International Capsule Endoscopy Research)coreStrategic or Co-development PartnerCEO Miguel Mascarenhas invited to join Scientific Committee of iCARE Group, a global leader shaping technological advancements in capsule endoscopy. Group fosters clinical and technological research through scientific collaborations.
• Centro Hospitalar Universitário São João / Faculdade de Medicina da Universidade do PortocoreStrategic or Co-development PartnerPrecision Medicine Unit collaboration for Masterclass in Precision Medicine events, advancing AI and big data in digestive healthcare through patient-centered tailored medicine initiatives.
• World-renowned healthcare institutions (data partners)coreStrategic or Co-development PartnerPartnerships providing over 2 million exams for algorithm training. Extensive and heterogeneous dataset from institutions worldwide enabling robust AI model development.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Medtronic (GI Genius): Medtronic's GI Genius is the most widely deployed AI module for colonoscopy polyp detection, directly competing with DigestAID's capsule and AI Live Vision products in gastroenterology departments. As a multi-hundred-billion-dollar medtech incumbent with an installed colonoscopy base, Medtronic has the regulatory clearances and commercial channels that DigestAID lacks.
• Olympus Corporation: Olympus is the global leader in endoscopy hardware and has been aggressively expanding into AI through internal development (EndoBRAIN) and acquisitions (Odin Vision, Satisfai Health). Its installed base of endoscopes in hospitals worldwide makes it both a potential channel partner and the principal long-term competitive threat to DigestAID.
• Fujifilm Healthcare: Fujifilm's endoscopy business (formerly Hitachi's) supplies a large share of GI endoscopy systems globally and is integrating AI-based lesion detection into its processors. Its CAD EYE platform competes head-to-head with DigestAID in colonoscopy AI-assisted detection.
• Pentax Medical (Hoya): Pentax Medical (Hoya Group) supplies flexible endoscopy systems used widely in gastroenterology and is investing in AI decision support features. It represents one of the three dominant endoscope incumbents whose installed-base advantage shapes hospital AI purchasing decisions relevant to DigestAID.

Direct peers

• Iterative Health: Iterative Health develops AI tools for GI endoscopy with a focus on inflammatory bowel disease and colonoscopy polyp detection, including the SKOUT and ScopeAI products. It is one of the closest direct competitors to DigestAID's IBD Smart and Deep Capsule, operating in the same gastroenterology AI category with similar B2B hospital GTM.
• Magentiq Eye: Magentiq Eye is an Israeli AI medical device company whose MAGENTIQ-COLO product automatically detects and characterizes polyps during colonoscopy, overlapping directly with DigestAID's colonoscopy-focused AI offerings. Both companies target gastroenterology departments with real-time lesion detection software.
• Virgo Surgical Video Solutions: Virgo builds AI-driven video capture, analysis, and quality improvement tools for endoscopy and surgical procedures, including GI indications. Its cloud-native platform overlaps with DigestAID's computer vision and severity-prioritization capabilities for endoscopy workflows.
• Odin Vision: Odin Vision is a UK-based AI endoscopy startup developing polyp detection and characterization software (Odin Art) for colonoscopy and upper GI procedures. It is a near-direct competitor to DigestAID's lesion detection products and was acquired by Olympus in 2023, illustrating incumbent bundling risk.

Emerging players

• RSIP Vision: RSIP Vision is an Israeli AI company providing computer vision algorithms for medical imaging including endoscopy, colonoscopy, and pathology. While broader in scope than DigestAID, it operates in the same algorithmic-interpretation niche and supplies AI modules to medical device OEMs, potentially competing for the same hospital software budgets.
• Motilent: Motilent is a UK-based medical imaging AI company focused on gastrointestinal motility analysis (GIQuant for MRI). It overlaps with DigestAID's motility cluster (Smart Mano, Smart Esophagus) and represents a focused emerging competitor in the AI motility diagnostic space.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/DigestAID
• LinkedInlinkedin.com/company/digestaid

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DigestAID